Iter Investments

Sensorium Therapeutics is a Boston-based drug discovery platform founded in 2021 that focuses on developing innovative FDA-approved psychoactive medicines. The company leverages an artificial intelligence product engine to discover and develop treatments for central nervous system diseases. By integrating historical human efficacy data of natural compounds, Sensorium Therapeutics aims to create new medicines characterized by unique pharmacological profiles and improved clinical success rates. This approach enhances the drug development processes for pharmaceutical companies, positioning Sensorium Therapeutics as a key player in the advancement of therapeutic solutions.

Beckley Retreats is a provider of virtual integration programs designed to support individuals with neurological and psychiatric disorders. The company specializes in facilitating safe and legal psychedelic retreats that offer scientific insights into healing practices. Beckley Retreats emphasizes holistic training and dedicated care, ensuring that participants have access to necessary medical support. Additionally, the company provides training and certification programs for practitioners, equipping them with the skills needed to guide others through their healing journeys.

Muse, developed by InteraXon, is a neurotechnology company that produces a headband designed to provide real-time feedback on brain activity during meditation. Founded in 2007 and headquartered in Toronto, Ontario, the company specializes in brain-computer interfaces, utilizing research-grade ambulatory electroencephalograms and EEG sensors. Muse’s technology captures brainwaves and translates them into digital signals, which are then processed to deliver insights on mental activity, heart rate, breathing, and body movements. This data enables users to enhance their meditation practices and mindfulness, fostering a deeper connection with their mental and physical states. Through its innovative hardware and software platform, Muse aims to support users in achieving greater mental clarity and well-being.

Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy. Our programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of our courses have specific prerequisites, a basic working knowledge of the mental health field and practice of psychotherapy is helpful. Our programs are interactive; we engage in discussion, demonstration, self-reflection exercises, and role plays. Some of our classes and programs are reserved for licensed clinicians, but many are open to anyone who wishes to attend.

Quantified Citizen is a developer of a mobile health research platform that aims to enhance scientific research by making it more accessible and participatory. The company empowers both citizen scientists and professional researchers to easily create and engage in their own scientific studies, thereby fostering a community dedicated to timely insights in health research. Its platform utilizes standardized health measures, allowing users to rapidly deploy behavioral research studies. Additionally, it provides a growing library of studies focused on various interventions, such as psychedelics and micro-dosing for mental health, enabling individuals to select studies that align with their interests while contributing to the advancement of global health and science.

Psilera is a biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases through the use of psychedelic compounds. The company focuses on creating a new class of neurological medicines, with its lead asset, PSIL-006, being a non-hallucinogenic derivative of psilocybin aimed at treating frontotemporal dementia. Psilera’s approach involves repurposing psychoactive natural products as foundational elements for next-generation therapies that enhance mental health. By prioritizing scientific excellence, Psilera seeks to transform the lives of individuals affected by cognitive, mood, and substance use disorders, marking a significant advancement in the field of mindful medicine.